First liquid biopsy from Guardant Health to receive FDA Approval

▴ guardant-health-receive-fda-approval-comprehensive-tumor-profiling-across-solid-cancer
First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health's Guardant360 CDx, gains credibility among oncologists in Asia, Middle East and Africa.

The U.S. Food and Drug Administration (FDA) has approved Guardant Health's liquid biopsy, Guardant360 CDx, for tumor mutation profiling in patients across all solid cancers.

For Guardant Health Asia, the Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test. Currently, the liquid biopsy is commercially available in 41 countries in AMEA. For advanced cancer patients, this FDA approval lends even greater credibility to the test and its ability to provide comprehensive genomic profiling information that is critical to their cancer treatment.

"This FDA approval is a significant milestone for us and it will certainly boost our efforts in offering Guardant360 as the preferred liquid biopsy option in AMEA. We remain committed to making the Guardant360 test available to as many advanced cancer patients as possible so that they can undergo complete genotyping and have the best opportunity to receive the right treatment for their cancer," said Mr Simranjit Singh, Chief Executive Officer of Guardant Health AMEA.

"The US FDA approval validates the technology behind the Guardant360 assay that we offer to advanced-stage cancer patients in AMEA. Treatment guidelines recommend testing for more than 20 different genomic biomarkers. Evaluating each mutation individually wastes time and delays treatment. With Guardant360, physicians and patients can feel confident that relevant genes are being assessed with a single blood test. Results are available within 7 days from receipt in the laboratory. This will help more patients start treatment sooner with appropriate precision cancer medicines," said, Chief Medical Officer Dr. Steve Olsen of Guardant Health AMEA.

Guardant Health AMEA hopes to accelerate wider adoption of guideline-recommended genomic profiling in clinical practice among medical oncologists so that advanced cancer patients in AMEA can benefit from reliable and comprehensive liquid biopsies such as Guardant360 and be treated quickly and accurately.

Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced-stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been ordered used by more than 7,000 oncologists and over 60 biopharmaceutical companies.

Tags : #GuardantHealth #Liquidbiopsy #USFDA #MrSimranjitSingh #DrSteveOlsen #CancerTreatment

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

From Algorithms to Actual Care: Is India’s AI Healthcare Dream Real?March 04, 2025
Lung Regeneration: Can Science Give Preterm Babies a Second Breath?March 04, 2025
Lung Regeneration: Can Science Give Preterm Babies a Second Breath?March 04, 2025
Lung Regeneration: Can Science Give Preterm Babies a Second Breath?March 04, 2025
The Great Indian Fat Crisis: Are 440 Million Overweight Indians the Price of Modernity?March 04, 2025
Neovantage Innovation Park Showcases Life Sciences Infrastructure at BioAsia 2025, Hosts Ministerial Visit and Miltenyi Biotec InaugurationMarch 03, 2025
University of Manchester invites applications for MA Digital Media, Culture and SocietyMarch 03, 2025
#EndLeprosy pathway is through stopping stigma against affected personsMarch 03, 2025
1.5 Million Bottles Recalled: Is Your ADHD Medication Safe?March 03, 2025
Dressed for Trust: Why Doctors Must Wear White Aprons AgainMarch 03, 2025
India’s Pharma Revolution: Can New Regulatory Reforms Unleash a $42 Billion Industry?March 01, 2025
Pregnant and Pained: Is Paracetamol Poisoning Our Unborn Children?March 01, 2025
Are Your Idlis Poisoning You? The Hidden Dangers of Plastic in Indian KitchensMarch 01, 2025
Rela Hospital Launches India’s First Intestinal Rehabilitation Centre to Expand Treatment Horizons Beyond TransplantationFebruary 28, 2025
Rela Hospital Launches India’s First Intestinal Rehabilitation Centre to Expand Treatment Horizons Beyond TransplantationFebruary 28, 2025
Olympus Announces Milestone for iTind(TM) Device with Expanded Availability Across Major APAC MarketsFebruary 28, 2025
7 Simple Breathing Exercises to Strengthen Your LungsFebruary 28, 2025
MedGenome launches Campaign ‘Care for the Rare’ to promote early detection of Rare DiseasesFebruary 27, 2025
Stuck in Slow Motion: How Bureaucracy is Choking India’s Pharma DreamFebruary 27, 2025
A New Spine, A New Life: Inside Kerala’s First 3D-Printed Titanium Cage SurgeryFebruary 27, 2025